Delving into the Latest Updates on Ganitumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Ganitumab (USAN/INN), AMG-479

Target

IGF-1R

Mechanism

IGF-1R antagonists(Insulin-like growth factor I receptor antagonists)

Therapeutic Areas

NeoplasmsImmune System DiseasesDigestive System Disorders+ [6]

Active Indication-

Inactive Indication

Advanced cancerAdvanced Lung Non-Small Cell Squamous CarcinomaAdvanced Malignant Solid Neoplasm+ [28]

Originator Organization

Amgen, Inc.

Active Organization-

Inactive Organization

Takeda Pharmaceutical Co., Ltd.

ImmunityBio, Inc.

Amgen, Inc.

+ [3]

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

RegulationOrphan Drug (US)

Login to view timeline

Structure/Sequence

Sequence Code 193853L

Source: *****

Sequence Code 13007076H

Source: *****

This early phase I trial studies the side effects of implanting and removing a microdevice in patients with sarcomas that have spread to other places in the body (metastatic) or have come back (recurrent). Microdevices are rice-sized devices that are implanted into tumor tissue and are loaded with 10 different drugs that are delivered at very small doses, or "microdoses," which may only affect a very small, local area inside the tumor. The purpose of this study is to determine which drugs delivered in the microdevice affect tumor tissue in patients with sarcomas.

Start Date25 Feb 2025

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

NCT04129151

/ TerminatedPhase 2IIT

Phase 2 Trial of Palbociclib and Ganitumab in Patients With Relapsed or Refractory Ewing Sarcoma

This research study is designed to study the combination of two drugs, palbociclib and ganitumab, as a potential treatment for Ewing sarcoma.
The names of the study drugs involved in this study are:
* Palbociclib
* Ganitumab

Start Date05 Dec 2019

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+2]

NCT03041701

/ TerminatedPhase 1/2IIT

A Phase I/II Trial of the Insulin-Like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in Patients With Embryonal and Alveolar Rhabdomyosarcoma

Background:
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood. Two types are embryonal RMS (ERMS) and alveolar RMS (ARMS). Dasatinib may block over-expression of a certain enzyme. Ganitumab may block a certain growth factor, which might suppress tumor growth. This drug combination may help slow tumor growth in people with ERMS and ARMS.
Objective:
To see if dasatinib combined with ganitumab is safe and shrinks or slows the growth of tumors in people with ERMS and ARMS.
Eligibility:
People any age who have ERMS or ARMS that did not respond to previous treatment and who can swallow tablets
Design:
Participants will be screened with:
Medical history
Physical exam
Blood, urine, and heart tests
Scans/x-rays
Tissue sample: This can be from previous surgery or biopsy.
Optional biopsy: A small piece of the tumor is removed with a needle.
Participants will be asked to co-enroll in another protocol.
Participants will get a drug interaction handout and wallet card that show what foods and medications to avoid.
Participants will be treated in cycles. The first cycle is 35 days, and the rest are 28 days. Participants will take dasatinib by mouth daily. They will get ganitumab through an intravenous (IV) every 2 weeks. They will have a physical exam every 1-2 weeks, and urine and heart tests before most cycles.
Participants will continue treatment as long as they do not have severe side effects, or their tumors do not get worse.
After ending treatment, participants will have a visit. This includes repeats of the screening tests.

Start Date07 Jul 2017

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Ganitumab

Login to view more data

100 Translational Medicine associated with Ganitumab

Login to view more data

100 Patents (Medical) associated with Ganitumab

Login to view more data

53

Literatures (Medical) associated with Ganitumab

01 Sep 2023·Clinical cancer research : an official journal of the American Association for Cancer Research

Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma.

Article

Author: Kaplan, Rosandra N ; Miettinen, Markku M ; Yohe, Marielle E ; Herrera, Kailey R ; Akshintala, Srivandana ; Palacio-Yance, Isabel ; Widemann, Brigitte C ; Glod, John W ; Chen, Helen X ; Helman, Lee J ; Dombi, Eva ; Pan, Alexander ; Bernstein, Donna ; Gross, Andrea M ; Derdak, Joanne ; Navid, Fariba ; Shern, Jack F ; Lei, Haiyan ; Heske, Christine M ; Sundby, R Taylor ; Steinberg, Seth M ; Mascarenhas, Leo

PURPOSE:

Antibodies against insulin-like growth factor (IGF) type 1 receptor have shown meaningful but transient tumor responses in patients with rhabdomyosarcoma (RMS). The SRC family member YES has been shown to mediate IGF type 1 receptor (IGF-1R) antibody acquired resistance, and cotargeting IGF-1R and YES resulted in sustained responses in murine RMS models. We conducted a phase I trial of the anti-IGF-1R antibody ganitumab combined with dasatinib, a multi-kinase inhibitor targeting YES, in patients with RMS (NCT03041701).

PATIENTS AND METHODS:

Patients with relapsed/refractory alveolar or embryonal RMS and measurable disease were eligible. All patients received ganitumab 18 mg/kg intravenously every 2 weeks. Dasatinib dose was 60 mg/m2/dose (max 100 mg) oral once daily [dose level (DL)1] or 60 mg/m2/dose (max 70 mg) twice daily (DL2). A 3+3 dose escalation design was used, and maximum tolerated dose (MTD) was determined on the basis of cycle 1 dose-limiting toxicities (DLT).

RESULTS:

Thirteen eligible patients, median age 18 years (range 8-29) enrolled. Median number of prior systemic therapies was 3; all had received prior radiation. Of 11 toxicity-evaluable patients, 1/6 had a DLT at DL1 (diarrhea) and 2/5 had a DLT at DL2 (pneumonitis, hematuria) confirming DL1 as MTD. Of nine response-evaluable patients, one had a confirmed partial response for four cycles, and one had stable disease for six cycles. Genomic studies from cell-free DNA correlated with disease response.

CONCLUSIONS:

The combination of dasatinib 60 mg/m2/dose daily and ganitumab 18 mg/kg every 2 weeks was safe and tolerable. This combination had a disease control rate of 22% at 5 months.

01 Jul 2023·Cancer medicine

Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma.

Article

Author: Fairchild, Grace ; Merriam, Priscilla ; Klega, Kelly ; Crompton, Brian D ; Posner, Andrew ; Guenther, Lillian M ; Stegmaier, Kimberly ; DuBois, Steven G ; Choy, Edwin ; Barker, Emma ; London, Wendy B ; Cavanaugh, Kerri L ; Shulman, David S ; Kao, Pei-Chi ; Bhushan, Ketki

BACKGROUND:

Ewing sarcoma (EWS) is an aggressive sarcoma with few treatment options for patients with relapsed disease. Cyclin-dependent kinase 4 (CDK4) is a genomic vulnerability in EWS that is synergistic with IGF-1R inhibition in preclinical studies. We present the results of a phase 2 study combining palbociclib (CDK4/6 inhibitor) with ganitumab (IGF-1R monoclonal antibody) for patients with relapsed EWS.

PATIENTS AND METHODS:

This open-label, non-randomized, phase 2 trial enrolled patients ≥12 years with relapsed EWS. All patients had molecular confirmation of EWS and RECIST measurable disease. Patients initially received palbociclib 125 mg orally on Days 1-21 and ganitumab 18 mg/kg intravenously on Days 1 and 15 of a 28-day cycle. The primary endpoints were objective response (complete or partial) per RECIST and toxicity by CTCAE. An exact one-stage design required ≥4 responders out of 15 to evaluate an alternative hypothesis of 40% response rate against a null of 10%. The study was closed following enrollment of the 10th patient due to discontinuation of ganitumab supply.

RESULTS:

Ten evaluable patients enrolled [median age 25.7 years (range 12.3-40.1)]. The median duration of therapy was 2.5 months (range 0.9-10.8). There were no complete or partial responders. Three of 10 patients had stable disease for >4 cycles and 2 had stable disease at completion of planned therapy or study closure. Six-month progression-free survival was 30% (95% CI 1.6%-58.4%). Two patients had cycle 1 hematologic dose-limiting toxicities (DLTs) triggering palbociclib dose reduction to 100 mg daily for 21 days. Two subsequent patients had cycle 1 hematologic DLTs at the reduced dose. Eighty percent of patients had grade 3/4 AEs, including neutropenia (n = 8), white blood cell decreased (n = 7), and thrombocytopenia (n = 5). Serum total IGF-1 significantly increased (p = 0.013) and ctDNA decreased during the first cycle.

CONCLUSIONS:

This combination lacks adequate therapeutic activity for further study, though a subset of patients had prolonged stable disease.

10 Apr 2023·Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group

Article

Author: Boron, Matthew ; Glade-Bender, Julia ; Krailo, Mark D. ; Eutsler, Eric ; Kolb, E. Anders ; Buxton, Allen ; Reid, Joel M. ; Chen, Helen X. ; Terezakis, Stephanie ; Daldrup-Link, Heike ; DuBois, Steven G. ; Randall, R. Lor ; Hill-Kayser, Christine ; Hayes, Andrea ; Gorlick, Richard G. ; Womer, Richard ; Lessnick, Stephen L. ; Crompton, Brian D. ; Arndt, Carola ; Janeway, Katherine A. ; Laack, Nadia ; Reed, Damon R. ; Rakheja, Dinesh ; Seibel, Nita L. ; Teot, Lisa

PURPOSE:

Monoclonal antibodies directed against insulin-like growth factor-1 receptor (IGF-1R) have shown activity in patients with relapsed Ewing sarcoma. The primary objective of Children's Oncology Group trial AEWS1221 was to determine if the addition of the IGF-1R monoclonal antibody ganitumab to interval-compressed chemotherapy improves event-free survival (EFS) in patients with newly diagnosed metastatic Ewing sarcoma.

METHODS:

Patients were randomly assigned 1:1 at enrollment to standard arm (interval-compressed vincristine/doxorubicin/cyclophosphamide alternating once every 2 weeks with ifosfamide/etoposide = VDC/IE) or to experimental arm (VDC/IE with ganitumab at cycle starts and as monotherapy once every 3 weeks for 6 months after conventional therapy). A planned sample size of 300 patients was projected to provide 81% power to detect an EFS hazard ratio of 0.67 or smaller for the experimental arm compared with the standard arm with a one-sided α of .025.

RESULTS:

Two hundred ninety-eight eligible patients enrolled (148 in standard arm; 150 in experimental arm). The 3-year EFS estimates were 37.4% (95% CI, 29.3 to 45.5) for the standard arm and 39.1% (95% CI, 31.3 to 46.7) for the experimental arm (stratified EFS-event hazard ratio for experimental arm 1.00; 95% CI, 0.76 to 1.33; 1-sided, P = .50). The 3-year overall survival estimates were 59.5% (95% CI, 50.8 to 67.3) for the standard arm and 56.7% (95% CI, 48.3 to 64.2) for the experimental arm. More cases of pneumonitis after radiation involving thoracic fields and nominally higher rates of febrile neutropenia and ALT elevation were reported on the experimental arm.

CONCLUSION:

Ganitumab added to interval-compressed chemotherapy did not significantly reduce the risk of EFS event in patients with newly diagnosed metastatic Ewing sarcoma, with outcomes similar to prior trials without IGF-1R inhibition or interval compression. The addition of ganitumab may be associated with increased toxicity.

2

News (Medical) associated with Ganitumab

14 Dec 2023

·www.businesswire.com

Insulin-Like Growth Factor Immunotherapy Advances: Crucial Findings on IGF-1R-Inhibiting Therapies Unveiled in Latest Research Publication - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This research explores the current landscape of immunotherapy treatments targeting the insulin-like growth factor-1 receptor (IGF-1R), a significant player in oncological advancements. The detailed study delves into the intricate relationships between IGF-1R and various cancer types, offering valuable insights into the prospects and challenges of IGF-1R inhibitors and associated therapeutic approaches. IGF-1R Immunotherapy's Role Beyond Oncology The research publication also captures the significance of IGF-1R inhibition in conditions beyond cancer, particularly noting its overexpression in immune cells related to thyroid ophthalmopathy in Graves' disease. Understanding the role of IGF-1R can lead to enhanced therapeutic interventions aimed at mitigating inflammatory processes and improving symptoms in affected patients. This robust body of work encapsulates the critical developments in IGF-1R-targeted immunotherapy, offering a treasure trove of information to stakeholders in the biopharmaceutical industry, research institutions, healthcare professionals, and policy-makers. Expanding IGF-1R Inhibition Therapeutics: A Glimpse into the Future The document underscores the complexities and potential of targeting IGF-1 receptor pathways, thrusting readers to the forefront of immunotherapeutic innovation. The nuanced findings in our report are crucial for guiding future research directions, optimizing treatment regimens, and ultimately enhancing patient care within the realm of precision medicine. The discoveries and analyses presented in this publication not only illuminate the path for future scientific inquiries but also underpin the strategic decisions that will shape the next generation of IGF-1R-targeted therapies. The implications of the findings extend to translational research, clinical application, and the broader biotech industry's approach to disease treatment and patient well-being. For those committed to staying abreast of the latest breakthroughs in targeted immunotherapy, exploring the wealth of information housed within the pages of this research document is indispensable. Key Highlights and Innovations in IGF-1R Immunotherapy The document presents critical developments through a tabulated competitors' overview, covering essential details such as drug codes, targets or mechanisms of action, compound classes, territorial reach of key competitors, indications, and the current stages of research and development. An in-depth project history section, providing links to relevant sources of information, including press releases, company homepages, academic abstracts, presentations, and annual reports, further enriches the report's content. Insightful analysis of past and ongoing clinical trials, including the performance of monoclonal antibodies such as figitumumab, ganitumab, and dalotuzumab in various phases of testing, with special emphasis on phase III clinical outcomes. Exploration of cutting-edge strategies that leverage IGF-1R's cell-signaling dynamics for targeted drug delivery, such as the use of antibody-drug conjugates and radioimmunoconjugates. For more information about this report visit https://www.researchandmarkets.com/r/litbge About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ImmunotherapyAACRASCO

15 Aug 2023

·pipelinereview.com

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

BARCELONA, Spain I August 15, 2023 I La Merie Publishing released its newest product reviewing the pipeline of IGF-1R or IGF-1 targeted drugs or immunotherapy candidates: IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review Target: Insulin-like growth factor-1 (IGF-1) & Receptor (IGF-1R Product Category: Antibody; Fusion Protein This product provides basic information on approved drugs and immunotherapy candidates in research and development targeting insulin-like growth factor-1 (IGF-1) or its receptor (IGF-1R). This product consists of: This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day. IGF-1R is a key member of the insulin-like growth factor (IGF) axis, which involves in cancer development, metastasis and cancer therapeutic resistance. Anti-IGF-1R monoclonal antibody is among the first major therapeutic agents for IGF-1R inhibition. These antibodies inhibit the binding between IGF-1R and its ligands, thereby blocking the activation of IGF-1R homodimer and IGF-1R/InsR hybrid, but not the InsR homodimer. A number of fully human monoclonal antibodies, which target the α subunit of IGF-1R, have demonstrated anti-tumor activities in pre-clinical studies. After completion of early phase clinical trials, three of the IGF-1R antibodies (figitumumab, ganitumab, and dalotuzumab) were tested in phase III clinical trials. Another strategy is inhibiting the binding of IGF ligands to the receptor which can inactivate IGF-1R. Due to the lack of a clear clinical benefit in these phase III trials, further clinical research was not pursued. Meanwhile, several firms are taking advantage of elevated IGF-1 signaling in cancers to deliver therapeutic payloads directly to tumor tissue, e.g. by antibody-drug conjugates or radioimmunoconjugates. These drug programs exploit the fact that IGF-1R, upon binding to its ligand or an antibody, undergoes receptor-mediated endocytosis, resulting in internalization of any bound molecules. Off-target toxicity is minimized because IGF-1R activity is mostly limited to internal compartments of the cell in vital organs such as the heart, and only a few tissues in the bladder, prostate and endometrium show low to moderate surface expression of IGF-1R. IGF-1R is a transmembrane tyrosine kinase receptor that plays a role in development, metabolism, and immune regulation, and is overexpressed in orbital fibroblasts (OFs), B, and T cells of thyroid ophthalmopathy in Graves' disease. Blocking IGF-1(R) signalling reduces the expression of downstream inflammatory factors, thereby inhibiting the synthesis of hyaluronic acid and other glycosaminoglycan caused by OFs activation, as well as related inflammatory reactions including tissue congestion and edema; inhibit adipocyte cellularization of OFs, thereby reducing the disease activity of patients with active thyroid ophthalmopathy and improving proptosis, diplopia, ocular congestion and edema and other symptoms and signs. The report “ IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review ” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/igf-1r-and-igf-1-targeted-immunotherapy-pipeline-review/ About La Merie Publishing La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers. La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest. SOURCE: La Merie Publishing

ImmunotherapyPhase 3Clinical Result

100 Deals associated with Ganitumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09908	Ganitumab	-	DB12205

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced cancer	Phase 3	US	ImmunityBio, Inc.	07 Apr 2011
Advanced cancer	Phase 3	US	Takeda Pharmaceutical Co., Ltd.	07 Apr 2011
Advanced cancer	Phase 3	JP	ImmunityBio, Inc.	07 Apr 2011
Advanced cancer	Phase 3	JP	Takeda Pharmaceutical Co., Ltd.	07 Apr 2011
Advanced cancer	Phase 3	AU	ImmunityBio, Inc.	07 Apr 2011
Advanced cancer	Phase 3	AU	Takeda Pharmaceutical Co., Ltd.	07 Apr 2011
Advanced cancer	Phase 3	AT	ImmunityBio, Inc.	07 Apr 2011
Advanced cancer	Phase 3	AT	Takeda Pharmaceutical Co., Ltd.	07 Apr 2011
Advanced cancer	Phase 3	BE	Takeda Pharmaceutical Co., Ltd.	07 Apr 2011
Advanced cancer	Phase 3	BE	ImmunityBio, Inc.	07 Apr 2011

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01318642 (CTgov)	Phase 2	Pancreatic adenocarcinoma \| Locally Advanced Pancreatic Adenocarcinoma	10	Placebo+Gemcitabine (Placebo + Gemcitabine)	rxmqmiflox(wougmiehwx) = sseimmdqop hsfgztqrbp (edddaxdfeb, ervqdwnqfz - gqzerxasmm) View more	-	08 Nov 2024
				AMG 479+Gemcitabine (AMG 479 20 mg/kg + Gemcitabine)	rxmqmiflox(wougmiehwx) = kcepoumdro hsfgztqrbp (edddaxdfeb, cpzbobqbzc - hqgfuammyj) View more
NCT00630552 (QUILT-2.019, CTgov)	Phase 1/2	Pancreatic adenocarcinoma \| Metastatic Pancreatic Cancer	138	AMG 655 (Phase 1b AMG 655 3mg/kg)	azdzsstxjq(rsvsioxknq) = hpymrctove egkiqujsch (xsnzguhnyk, klehbkdzyx - wejqnrbwtm) View more	-	17 Oct 2024
				AMG 655 (Phase 1b AMG 655 10mg/kg)	azdzsstxjq(rsvsioxknq) = ouzuwjospc egkiqujsch (xsnzguhnyk, rdnnvwczgr - pzpmymvmcg) View more
NCT00807612 (QUILT-2.017, CTgov)	Phase 1/2	Advanced Lung Non-Small Cell Squamous Carcinoma	15	AMG 479+Carboplatin+Paclitaxel (AMG 479 18 mg/kg + Paclitaxel/Carboplatin)	gdxrrgmdqw(mseganuomy) = niqmqfrmhp dmyxcceijs (zyciqezwxm, qodiinprnr - xuazvwaixk) View more	-	25 Sep 2024
				Ganitumab+Carboplatin+Paclitaxel (Ganitumab 18 mg/kg + Paclitaxel/Carboplatin)	cmccajajty(qwyayykwiq) = rlhbvfrzfg glqgpxupxk (uooksrkalk, rdnsisomwo - rtzdtuwibg) View more
NCT00626106 (QUILT-2.015, CTgov)	Phase 2	Hormone receptor positive breast cancer \| Neoplasm Metastasis	156	AMG 479 (Arm A: AMG 479 12 mg/kg IV Q2W + Endocrine Therapy)	dprwkzwkpc(xsknsnitjp) = tddpvpqrgc dzokykxsmk (xkmdarqgcy, aohklvfvxk - qstejnwbnu) View more	-	19 Sep 2024
				Placebo (Arm B: Placebo IV Q2W + Endocrine Therapy)	dprwkzwkpc(xsknsnitjp) = yivilznutp dzokykxsmk (xkmdarqgcy, jcxlxwtbxf - hsmmmvjetb) View more
NCT00791154 (SCLC, CTgov)	Phase 1/2	Extensive stage Small Cell Lung Cancer	213	Ganitumab (Phase 2 Ganitumab)	whmysgvist(afdiypoque) = ckrohudkkv atqtslbdfl (dgjaeyghho, phwkhexywf - bherhzxlpa) View more	-	23 Aug 2024
				placebo+etoposide+carboplatin+cisplatin (Phase 2 Placebo)	whmysgvist(afdiypoque) = fypshnjlnb atqtslbdfl (dgjaeyghho, yepuojsuny - csfxmfbasu) View more
NCT00819169 (CTgov)	Phase 1/2	Sarcoma \| Ovarian Cancer \| Neoplasm Metastasis ... View more	89	AMG 479+AMG 655 (Part 1 Cohort 1)	ioklrryxfi(xhqgkqedtp) = pubnycoudx xqbdzoryjo (zjkyawvked, erpvxtldlu - hajusfrkmn) View more	-	20 Aug 2024
				AMG 479+AMG 655 (Part 1 Cohort 2)	ioklrryxfi(xhqgkqedtp) = bnvutcpnkf xqbdzoryjo (zjkyawvked, atbtdxybqz - zljpwikjxz) View more
NCT04129151 (CTgov)	Phase 2	Recurrent Ewing Sarcoma \| Refractory Ewing Sarcoma	10	Ganitumab+palbociclib	jhirlayqir(nqqexiulmt) = qltzcfxgno hbveyefink (pldwqulynh, ijcvwhopgk - khkhareviy) View more	-	17 Jul 2024
NCT01231347 (QUILT-2.014 \| GAMMA \| GAMMA trial, CTgov)	Phase 3	Pancreatic adenocarcinoma \| Metastatic Pancreatic Cancer \| Advanced Malignant Solid Neoplasm ... View more	800	AMG 479+gemcitabine (AMG 479 12 mg/kg Dose + Gemcitabine)	goekmqyknt(qzoltasovb) = gumbmrrdeh vqcuhsfvwm (glcnlpscis, vhkxdupcon - kefgggqkoh) View more	-	16 Jul 2024
				AMG 479+gemcitabine (AMG 479 20 mg/kg + Gemcitabine)	goekmqyknt(qzoltasovb) = eumjlrtxcf vqcuhsfvwm (glcnlpscis, fnbdlpliel - ubhuclxitw) View more
NCT03041701 (Pubmed)	Phase 1	Rhabdomyosarcoma	14	Ganitumab	ujrjuvrsft(rzfdpzyoci) = kirqbrbesx fzwprfjadx (vgwjtnjupn )	-	03 Jul 2023
NCT04129151 (ASCO2022) Manual	Phase 2	Recurrent Ewing Sarcoma	10	palbociclib+ganitumab	lpajefmjhe(xzoagkmvbn) = srqgswgret zoeytdsdxf (nqpaujdphp ) View more	Negative	02 Jun 2022